{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:28:01Z","timestamp":1791354481623,"version":"4.3.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1007\/s10637-005-1444-0","type":"journal-article","created":{"date-parts":[[2005,7,12]],"date-time":"2005-07-12T14:00:00Z","timestamp":1121176800000},"page":"357-361","source":"Crossref","is-referenced-by-count":342,"title":["Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme"],"prefix":"10.1007","volume":"23","author":[{"given":"Susan M.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Ian","family":"Robins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Raizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Aldape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen R.","family":"Lamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Dancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Prados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"North American Brain Tumor Consortium and the National Cancer Institute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"1444_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1215\/S1522851702000029","volume":"4","author":"CB Knobbe","year":"2002","unstructured":"Knobbe CB, Merlo A, Reifenberger G: Pten signaling in gliomas. Neuro-oncol 4: 196\u2013211, 2002","journal-title":"Neuro-oncol"},{"key":"1444_CR2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9440(10)61702-6","volume":"159","author":"H Sasaki","year":"2001","unstructured":"Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN: PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159: 359\u2013367, 2001","journal-title":"Am J Pathol"},{"key":"1444_CR3","first-page":"1820","volume":"59","author":"T Sano","year":"1999","unstructured":"Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA: Differential expression of MMAC\/PTEN in glioblastoma multiforme: Relationship to localization and prognosis. Cancer Res 59: 1820\u20131824, 1999","journal-title":"Cancer Res"},{"key":"1444_CR4","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/jnci\/93.16.1246","volume":"93","author":"JS Smith","year":"2001","unstructured":"Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O\u2019Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246\u20131256, 2001","journal-title":"J Natl Cancer Inst"},{"key":"1444_CR5","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","volume":"19","author":"M Hidalgo","year":"2000","unstructured":"Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680\u20136686, 2000","journal-title":"Oncogene"},{"key":"1444_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0006-2952(02)01263-7","volume":"64","author":"J Chen","year":"2002","unstructured":"Chen J, Fang Y: A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 64: 1071\u20131077, 2002","journal-title":"Biochem Pharmacol"},{"key":"1444_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","volume":"103","author":"T Schmelzle","year":"2000","unstructured":"Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 103: 253\u2013262, 2000","journal-title":"Cell"},{"key":"1444_CR8","first-page":"1527","volume":"61","author":"B Geoerger","year":"2001","unstructured":"Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61: 1527\u20131532, 2001","journal-title":"Cancer Res"},{"key":"1444_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/B:DRUG.0000036685.72140.03","volume":"22","author":"SM Chang","year":"2004","unstructured":"Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD, North American Brain Tumor Consortium and the National Cancer Institute: Phase I\/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs (in press) 22: 427\u2013435, 2004","journal-title":"Invest New Drugs (in press)"},{"key":"1444_CR10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277\u20131280, 1990","journal-title":"J Clin Oncol"},{"key":"1444_CR11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909\u2013918, 2004","journal-title":"J Clin Oncol"},{"key":"1444_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1215\/S1522851702000121","volume":"4","author":"FF Lang","year":"2002","unstructured":"Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA: Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies. Neuro-oncol 4: 268\u2013277, 2002","journal-title":"Neuro-oncol"},{"key":"1444_CR13","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1074\/jbc.M309999200","volume":"279","author":"JF Gera","year":"2004","unstructured":"Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279: 2737\u20132746, 2004","journal-title":"J Biol Chem"},{"key":"1444_CR14","first-page":"2742","volume":"63","author":"G Choe","year":"2003","unstructured":"Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS: Analysis of the phosphatidylinositol 3\u2019-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63: 2742\u20132746, 2003","journal-title":"Cancer Res"},{"key":"1444_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ijc.11085","volume":"105","author":"M Klingler-Hoffmann","year":"2003","unstructured":"Klingler-Hoffmann M, Bukczynska P, Tiganis T: Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer 105: 331\u2013339, 2003","journal-title":"Int J Cancer"},{"key":"1444_CR16","first-page":"169","volume":"14","author":"R Schober","year":"1995","unstructured":"Schober R, Bilzer T, Waha A, Reifenberger G, Wechsler W, von Deimling A, Wiestler OD, Westphal M, Kemshead JT, Vega F, Delattre JY, Stasiecki-Steinfeld P: The epidermal growth factor receptor in glioblastoma: Genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol 14: 169\u2013174, 1995","journal-title":"Clin Neuropathol"},{"key":"1444_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1054\/drup.2002.0227","volume":"4","author":"S Huang","year":"2001","unstructured":"Huang S, Houghton PJ: Mechanisms of resistance to rapamycins. Drug Resist Updat 4: 378\u2013391, 2001","journal-title":"Drug Resist Updat"},{"key":"1444_CR18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/mol.54.5.815","volume":"54","author":"H Hosoi","year":"1998","unstructured":"Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence JC, Jr., Houghton PJ: Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 54: 815\u2013824, 1998","journal-title":"Mol Pharmacol"},{"key":"1444_CR19","first-page":"7291","volume":"62","author":"JS Eshleman","year":"2002","unstructured":"Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN: Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62: 7291\u20137297, 2002","journal-title":"Cancer Res"},{"key":"1444_CR20","first-page":"6141","volume":"62","author":"V Grunwald","year":"2002","unstructured":"Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62: 6141\u20136145, 2002","journal-title":"Cancer Res"},{"key":"1444_CR21","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1038\/sj.onc.1203918","volume":"19","author":"M Tanaka","year":"2000","unstructured":"Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB: MMAC1\/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19: 5406\u20135412, 2000","journal-title":"Oncogene"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-1444-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-005-1444-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-1444-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-1444-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T13:00:32Z","timestamp":1678539632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-005-1444-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["1444"],"URL":"https:\/\/doi.org\/10.1007\/s10637-005-1444-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}